RE-BVS – Piemonte Repository

Sfoglia per AUTORE
FRESA A
Collezione AO Cuneo

Items : 4

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. in Hematological oncology / Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Laurenti L; Cuneo A; Foà R; Trentin L; Coscia M; Rigolin GM; Mattiello V; Gattei V; Sportoletti P; Scortechini I; Moia R; Gentile M; Catania G; Loseto G; Chiurazzi F; Malerba L; De Paolis MR; Angeletti I; Ferrari A; Giordano A; Baratè C; Quaresmini G; Leone MMA; Farina L; Fresa A; Piciocchi A; Vitale C; Reda G; Visentin A; et alii...

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. in American journal of hematology / Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Alessandria

Cuneo A; Trentin L; Foà R; Molica S; Laurenti L; Pravato S; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Coscia M; Piazza F; Reda G; Fresa A; Ciolli S; Scarfò L; Sportoletti P; Pietrasanta D; Vitale C; Mauro FR; Cibien F; Visentin A;

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. in Journal of hematology & oncology / J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.

2022
AO Cuneo
ASL Vercelli
ASL Cuneo 1
AOU Alessandria

Ghia P; Stamatopoulos K; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Carrier M; Wróbel T; Segundo LYS; Varettoni M; Visentin A; Vitale C; Vukovic V; Shrestha A; Šimkovi? M; Smirnova S; Špa?ek M; Sportoletti P; Stanca O; Wasik-Szczepanek E; Stavroyianni N; Te Raa D; Tomic K; Tonino S; Trentin L; Van Der Spek E; van Gelder M; et alii...

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study. in Frontiers in oncology / Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022.

2022
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria

Laurenti L; Trentin L; Cuneo A; Foà R; Ghia P; Coscia M; Reda G; Scarfò L; Angotzi F; Cellini A; Pravato S; Molica S; Marchetti M; Murru R; Gozzetti A; Gentile M; Rigolin GM; Quaglia FM; Sanna A; Sportoletti P; Cibien F; Mattiello V; Mauro FR; Catania G; Fresa A; Vitale C; Visentin A;